Journal of Virus Eradication

Papers
(The TQCC of Journal of Virus Eradication is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Impact of COVID-19 on people living with HIV: A review62
Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, I61
Altruism: Scoping review of the literature and future directions for HIV cure-related research16
Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers14
Achievements and gaps to provide pre-exposure prophylaxis (PrEP) for women across the European Region – Results from a European survey study11
Re-examining the HIV ‘functional cure’ oxymoron: Time for precise terminology?11
A viewpoint: The 2022 monkeypox outbreak11
Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom11
Langya virus outbreak in China, 2022: Are we on the verge of a new pandemic?9
Vaccination with inactivated virus against low pathogenic avian influenza subtype H9N2 does not prevent virus transmission in chickens9
The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review8
A landscape analysis of HIV cure-related clinical research in 20198
Time for revolution? Enhancing meaningful involvement of people living with HIV and affected communities in HIV cure-focused science8
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study7
Antiviral strategies targeting herpesviruses7
Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers7
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper7
Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women's perceptions, barriers and preferences6
Motivations, barriers and experiences of participants in an HIV reservoir trial6
Bringing social context into global biomedical HIV cure-related research: An urgent call to action6
Comparison of methods to quantify inducible HIV-1 outgrowth6
Antiviral activity of silver nanoparticles against the influenza A virus6
Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis6
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies5
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV5
Hepatitis C in Uganda: Identification of infected blood donors for micro-elimination5
Substantial uneven proliferation of CD4+ T cells during recovery from acute HIV infection is sufficient to explain the observed expanded clones in the HIV reservoir5
Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research5
Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China5
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection5
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications5
Bispecific antibody-derived molecules to target persistent HIV infection4
Hypothetical questionnaires may overestimate willingness to participate in HIV cure research: Comparison of a cross-sectional survey to actual willingness to participate in an HIV cure study in the Ne4
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection4
Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness mo4
Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform4
Impact of hepatitis B vaccination programs in Vietnam evaluated by estimating HBsAg prevalence4
High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era3
Combination strategies to durably suppress HIV-1: Soluble T cell receptors3
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir3
Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses3
Menopause care in women living with HIV in the UK - A review3
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-23
Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China3
Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection3
A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France3
Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling3
Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model3
Influenza A (H6N6) viruses isolated from chickens replicate in mice and human lungs without prior adaptation3
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA2
Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 20182
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV2
Antiviral activity of nitazoxanide against Morbillivirus infections2
OP 3.7 – 00099 Cohort-specific Adaptation of the Intact Proviral DNA Assay (IPDA) to HIV-1 subtypes A1, D, and recombinants2
Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy2
Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study2
Heat shock protein: a double-edged sword linking innate immunity and hepatitis B virus infection2
Is the human T-cell lymphotropic virus type 2 in the process of endogenization into the human genome?2
OP 7.3 – 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A53452
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting2
OP 3.4 – 00197 Infected naïve CD4+ T cells in children with HIV can proliferate and persist on ART2
Mass immunisation to eradicate Japanese encephalitis: Real-world evidence from Guizhou Province in 2005–20212
Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice2
OP 6.2 – 00195 Targeted genome engineering of human t cells in vivo for HIV cure1
The ethical case for placebo control in HIV-cure-related studies with ART interruption1
OP 3.6 – 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation1
OP 6.3 – 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia1
Assessment of dengue virus threat to blood safety and community health: A single center study in northern Egypt1
OP 1.2 – 00157 HIV Silencing and Cell Survival Signatures of HIV-Infected CD4 T Cell Transcriptomes under Antiretroviral Therapy (ART)1
Engagement of AKT and ERK signaling pathways facilitates infection of human neuronal cells with West Nile virus1
OP 8.2 – 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection1
OP 6.8 – 00102 In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-eCD4-Ig therapy1
OP 1.10 – 00210 Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART1
OP 6.7 – 00044 Long-term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques1
The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection1
Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand1
OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR tri1
Intact provirus and integration sites analysis in acute HIV-1 infection and changes after one year of early antiviral therapy1
OP 5.3 – 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption1
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral1
OP 6.4 – 00096 High-efficiency CRISPR/Cas9-mediated disruption of ccr5 in human hematopoietic stem progenitor cells generates HIV-refractory immune systems1
OP 3.1 HIV Persistence in women, an update1
OP 3.3 – 00030 Inducible replication-competent HIV proviruses persist in memory CD4+ T cells expressing high levels of the integrin VLA-4 (α4β1)1
OP 3.5 – 00152 HIV-1RNA+infected CD4 T cell burden in acute HIV-1 infection and association with inflammatory markers1
The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample1
OP 1.1 Sequencing HIV: Significance and Impact1
OP 3.2 – 00056 Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management1
Key highlights from the international AIDS society (IAS) conference 20211
OP 8.4 – 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption1
OP 1.6 – 00138 Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms1
OP 6.1 It's a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure1
Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa1
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach1
OP 1.7 – 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir1
Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents1
OP 7.2 – 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial1
The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture1
OP 3.8 – 00066 Characterization of the HIV-1 viral reservoir in subtype B early treated individuals1
OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir1
Patient acceptability of, and attitudes towards, hepatitis B cure research – A scoping review and identification of knowledge gaps1
OP 6.6 – 00134 Viral Suppression in SHIV-infected Rhesus Macaques following AAVmediated Delivery of Closer-to-germline Monoclonal Antibodies1
Commentary title: COVID-19 research, Africa, and global health1
OP 8.3 – 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccin1
OP 1.4 – 00053 Definitive evidence of a persistent HIV reservoir in human brain myeloid cells despite ART1
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings1
OP 8.6 – 00166 Autologous neutralizing antibody responses in bnAb-treated rhesus macaques1
OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs1
OP 8.5 – 00104 TGF-beta Blockade to Stop HIV White Noise: a New “Release and Kill” HIV Strategy1
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium1
OP 2.8 – 00193 Enhancing PKC Modulator HIV Latency Reversing Agents1
OP 1.5 – 00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment1
OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia1
OP 7.4 – 00012 Series of Jojo. A way to disseminate HIV Cure information in a community language1
0.059960842132568